NTBL Notable Labs Ltd: Multiplikator forward rega marang pendapatan
High barriers to entry for Notable Labs, Ltd. (NTBL) are driven by R&D costs and stringent FDA oversight. The forward P/S multiple helps assess market expectations, where 7.70 reflects the most recent value of the metric. Business efficiency relies on the express delivery of biosamples, while growth potential is based on increasing clinic demand for predictive diagnostics in oncology.
Notable Labs Corp (NTBL) - rincian metrik lan laporan keuangan
- rega pasar lan target rega analis:
- data kapitalisasi saham perusahaan:
- rincian valuasi buku bisnis:
- statistik kawajiban utang lan likuiditas:
Utang marang Ekuitas Notable Labs, Ltd.|NTBL - Utang jangka dawa marang ekuitas|Utang jangka cendhak marang modal Notable Labs, Ltd.|NTBL - Utang kumulatif perusahaan|Utang marang nilai buku Notable Labs Corp|NTBL - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Notable Labs|Rasio cepet notablelabs.com
- rincian asil keuangan lan kelipatan valuasi:
NTBL - Bathi resik|Proyeksi bathi mangsa ngarep Notable Labs, Ltd.|NTBL - Rasio rega marang bathi|Rega marang bathi mangsa ngarep Notable Labs Inc.|NTBL - Kapitalisasi marang bathi resik kanthi nimbang wutah|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Notable Labs Corp|NTBL - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Notable Labs|NTBL - Bathi saben saham sajrone rolas wulan pungkasan|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan notablelabs.com|NTBL - Wutah bathi resik saben siji saham kanggo taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Notable Labs, Ltd.
- data total pendapatan lan volume dodolan:
Analisis wiwitan perusahaan:Notable Labs (NTBL)
AI-driven screening of live cells for oncology therapy selection by Notable Labs, Ltd. (NTBL) creates significant value, which is reflected in the expected price-to-sales ratio. This indicator compares current market capitalization with projected sales volume, allowing investors to instantly determine the extent of the business's market discount or premium relative to competitors while assessing the stability of the cost of capital over time.
Pesaing wigati
Rasio rega marang prakiraan pendapatan BeiGene ONC|Halozyme Therapeutics, Inc. (HALO) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|RVMD: Multiplikator forward rega marang pendapatan|Ascentage Pharma Corp - Rasio rega marang pendapatan sing dikarepake|CGON: Multiplikator Forward P/S|urogen.com (URGN) - Multiplikator Forward P/S|BCAX (Bicara Therapeutics) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan PSNL|Rasio rega marang prakiraan pendapatan Erasca Corp (ERAS)|Rasio rega marang prakiraan pendapatan DCTH (Delcath Corp)|Multiplikator Forward P/S YMAB (Y-mAbs Therapeutics)|aurabiosciences.com (AURA) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|CADL: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan ARAY (Accuray Inc)|sellaslifesciences.com (SLS) - Rasio rega marang prakiraan pendapatan|ACTU (Actuate Therapeutics Inc) - Rasio rega marang prakiraan pendapatan|CTOR (Citius Oncology, Inc.) - Multiplikator Forward P/S|Multiplikator Forward P/S TuHURA|Multiplikator Forward P/S TARA|Rasio rega marang prakiraan pendapatan FATE (Fate Therapeutics Inc)|Rasio rega marang prakiraan pendapatan Aadi Bioscience WHWK|Rasio kapitalisasi marang dodolan sing dikarepake TScan Therapeutics Inc (TCRX)|CSBR: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan XBIT (XBiotech Inc.)|cel-sci.com (CVM) - Rasio rega marang prakiraan pendapatan|OSTX (OS Therapies Inc.) - Rasio rega marang prakiraan pendapatan|Multiplikator forward rega marang pendapatan RADX|ARTV (Artiva) - Rasio rega marang pendapatan sing dikarepake|Multiplikator Forward P/S ANL|verupharma.com - Kapitalisasi marang prakiraan pendapatan|Tempest Therapeutics, Inc. - Multiplikator forward rega marang pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake Xilio Therapeutics Inc (XLO)|RENB - Rasio rega marang prakiraan pendapatan|MURA (Mural Oncology plc) - Kapitalisasi marang prakiraan pendapatan|KAPA (kairospharma.com) - Multiplikator forward rega marang pendapatan|OKUR: Rasio rega marang pendapatan sing dikarepake|GDTC (CytoMed Therapeutics Ltd) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan CRIS|Rasio rega marang prakiraan pendapatan Apollomics, Inc. (APLM)|Rasio rega marang prakiraan pendapatan THAR (Tharimmune Corporation)|Multiplikator Forward P/S ADVB (Advanced Biomed)|GNPX - Multiplikator forward rega marang pendapatan|Calidi Bio - Multiplikator Forward P/S|SBFM - Multiplikator Forward P/S|xeneticbio.com (XBIO) - Rasio rega marang prakiraan pendapatan|Kapitalisasi marang prakiraan pendapatan SLRX|PPBT (Purple Biotech) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan AON (AONC)|Multiplikator Forward P/S BGNE|CKPT - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Rasio rega marang prakiraan pendapatan Elevation Oncology, Inc. ELEV|Rega forward marang dodolan ICAD|IKNA: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan VIRX (Viracta Therapeutics)|MOR: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan NAYA Biosciences Inc|Multiplikator forward rega marang pendapatan AAPGV
